In advanced non-small cell lung cancer, ganetspib was evaluated in the phase 2 GALAXY-1 trial Ganetespib did not meet its primary endpoint of progression-free survival in either of two pre-specified subgroups: patients with elevated lactate dehydrogenase (eLDH) and mutated KRAS (mKRAS)27. This evidence concerns the gene KRAS and non-small cell lung carcinoma.